{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T21:17:46Z","timestamp":1774127866490,"version":"3.50.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10557-024-07652-3","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T03:48:57Z","timestamp":1733802537000},"page":"1567-1584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reassessing Ivabradine: Potential Benefits and Risks in Atrial Fibrillation Therapy"],"prefix":"10.1007","volume":"39","author":[{"given":"Dorsa","family":"Alijanzadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrzad","family":"Moghim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paniz","family":"Zarand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Ali","family":"Akbarzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasaman","family":"Zarinfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6694-6542","authenticated-orcid":false,"given":"Isa","family":"Khaheshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"issue":"5","key":"7652_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.phrs.2006.03.006","volume":"53","author":"D DiFrancesco","year":"2006","unstructured":"DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53(5):399\u2013406.","journal-title":"Pharmacol Res"},{"issue":"14","key":"7652_CR2","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","volume":"70","author":"JS Koruth","year":"2017","unstructured":"Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The clinical use of ivabradine. J Am Coll Cardiol. 2017;70(14):1777\u201384.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"7652_CR3","first-page":"442","volume":"94","author":"C Gutierrez","year":"2016","unstructured":"Gutierrez C, Blanchard DG. Diagnosis and treatment of atrial fibrillation. Am Fam Physician. 2016;94(6):442\u201352.","journal-title":"Am Fam Physician"},{"issue":"12","key":"7652_CR4","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/j.hrthm.2014.08.007","volume":"11","author":"RL Verrier","year":"2014","unstructured":"Verrier RL, Bonatti R, Silva AF, et al. If inhibition in the atrioventricular node by ivabradine causes rate-dependent slowing of conduction and reduces ventricular rate during atrial fibrillation. Heart Rhythm. 2014;11(12):2288\u201396. https:\/\/doi.org\/10.1016\/j.hrthm.2014.08.007.","journal-title":"Heart Rhythm"},{"issue":"1","key":"7652_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ijcard.2014.04.183","volume":"175","author":"G Moubarak","year":"2014","unstructured":"Moubarak G, Logeart D, Cazeau S, Cohen SA. Might ivabradine be useful in permanent atrial fibrillation? Int J Cardiol. 2014;175(1):187\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2014.04.183.","journal-title":"Int J Cardiol"},{"issue":"4","key":"7652_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1097\/fjc.0000000000001209","volume":"79","author":"Z Wang","year":"2022","unstructured":"Wang Z, Wang W, Li H, et al. Ivabradine and atrial fibrillation: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2022;79(4):549\u201357. https:\/\/doi.org\/10.1097\/fjc.0000000000001209.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"9744","key":"7652_CR7","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875\u201385. https:\/\/doi.org\/10.1016\/S0140-6736(10)61198-1.","journal-title":"Lancet"},{"issue":"2","key":"7652_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1517\/17425255.2014.876005","volume":"10","author":"GM Rosa","year":"2014","unstructured":"Rosa GM, Ferrero S, Ghione P, Valbusa A, Brunelli C. An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure. Expert Opin Drug Metab Toxicol. 2014;10(2):279\u201391. https:\/\/doi.org\/10.1517\/17425255.2014.876005.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"7652_CR9","unstructured":"National Center for Biotechnology Information. PubChem Compound Summary for CID 132999, Ivabradine. 2023. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Ivabradine. Accessed 5 Dec 2024."},{"key":"7652_CR10","doi-asserted-by":"publisher","first-page":"114777","DOI":"10.1016\/j.biopha.2023.114777","volume":"164","author":"M Chen","year":"2023","unstructured":"Chen M, Wu Q. Roles and mechanisms of natural drugs on sinus node dysfunction. Biomed Pharmacother. 2023;164:114777. https:\/\/doi.org\/10.1016\/j.biopha.2023.114777.","journal-title":"Biomed Pharmacother"},{"key":"7652_CR11","doi-asserted-by":"publisher","unstructured":"Low PA, editor. Primer on the autonomic nervous system. Academic Press; 2011 Nov 3. https:\/\/doi.org\/10.1016\/B978-0-12-386525-0.00001-1.","DOI":"10.1016\/B978-0-12-386525-0.00001-1"},{"issue":"1","key":"7652_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.pharmthera.2005.01.005","volume":"107","author":"M Baruscotti","year":"2005","unstructured":"Baruscotti M, Bucchi A, DiFrancesco D. Physiology and pharmacology of the cardiac pacemaker (\u201cfunny\u201d) current. Pharmacol Ther. 2005;107(1):59\u201379. https:\/\/doi.org\/10.1016\/j.pharmthera.2005.01.005.","journal-title":"Pharmacol Ther"},{"issue":"16","key":"7652_CR13","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2165\/00003495-200464160-00003","volume":"64","author":"D DiFrancesco","year":"2004","unstructured":"DiFrancesco D, Camm JA. Heart rate lowering by specific and selective if current inhibition with ivabradine. Drugs. 2004;64(16):1757\u201365. https:\/\/doi.org\/10.2165\/00003495-200464160-00003.","journal-title":"Drugs"},{"issue":"12","key":"7652_CR14","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/nrd3576","volume":"10","author":"O Postea","year":"2011","unstructured":"Postea O, Biel M. Exploring HCN channels as novel drug targets. Nat Rev Drug Discovery. 2011;10(12):903\u201314. https:\/\/doi.org\/10.1038\/nrd3576.","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"7652_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/sj.bjp.0706940","volume":"150","author":"C Thollon","year":"2007","unstructured":"Thollon C, Bedut S, Villeneuve N, et al. Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity. Br J Pharmacol. 2007;150(1):37\u201346.","journal-title":"Br J Pharmacol"},{"key":"7652_CR16","doi-asserted-by":"crossref","unstructured":"Lee C-H, MacKinnon R. Structures of the human HCN1 hyperpolarization-activated channel. Cell. 2017;168(1):111\u201320. e11.","DOI":"10.1016\/j.cell.2016.12.023"},{"issue":"16","key":"7652_CR17","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.2174\/1568026616999160315130832","volume":"16","author":"M Novella Romanelli","year":"2016","unstructured":"Novella Romanelli M, Sartiani L, Masi A, et al. HCN channels modulators: the need for selectivity. Curr Top Med Chem. 2016;16(16):1764\u201391.","journal-title":"Curr Top Med Chem"},{"issue":"3","key":"7652_CR18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1152\/physrev.00029.2008","volume":"89","author":"M Biel","year":"2009","unstructured":"Biel M, Wahl-Schott C, Michalakis S, Zong X. Hyperpolarization-activated cation channels: from genes to function. Physiol Rev. 2009;89(3):847\u201385. https:\/\/doi.org\/10.1152\/physrev.00029.2008.","journal-title":"Physiol Rev"},{"issue":"3","key":"7652_CR19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/CIRCRESAHA.109.208041","volume":"106","author":"D DiFrancesco","year":"2010","unstructured":"DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res. 2010;106(3):434\u201346.","journal-title":"Circ Res"},{"issue":"11","key":"7652_CR20","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1161\/01.RES.0000101913.95604.B9","volume":"93","author":"H Dobrzynski","year":"2003","unstructured":"Dobrzynski H, Nikolski VP, Sambelashvili AT, et al. Site of origin and molecular substrate of atrioventricular junctional rhythm in the rabbit heart. Circ Res. 2003;93(11):1102\u201310. https:\/\/doi.org\/10.1161\/01.RES.0000101913.95604.B9.","journal-title":"Circ Res"},{"key":"7652_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.coph.2013.12.005","volume":"15","author":"C Wahl-Schott","year":"2014","unstructured":"Wahl-Schott C, Fenske S, Biel M. HCN channels: new roles in sinoatrial node function. Curr Opin Pharmacol. 2014;15:83\u201390. https:\/\/doi.org\/10.1016\/j.coph.2013.12.005.","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"7652_CR22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00395-009-0031-5","volume":"104","author":"PA Schweizer","year":"2009","unstructured":"Schweizer PA, Yampolsky P, Malik R, et al. Transcription profiling of HCN-channel isotypes throughout mouse cardiac development. Basic Res Cardiol. 2009;104(6):621\u20139. https:\/\/doi.org\/10.1007\/s00395-009-0031-5.","journal-title":"Basic Res Cardiol"},{"issue":"8","key":"7652_CR23","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jacc.2014.06.1155","volume":"64","author":"A Schweizer Patrick","year":"2014","unstructured":"Schweizer Patrick A, Schr\u00f6ter J, Greiner S, et al. The symptom complex of familial sinus node dysfunction and myocardial noncompaction is associated with mutations in the HCN4 channel. J Am Coll Cardiol. 2014;64(8):757\u201367. https:\/\/doi.org\/10.1016\/j.jacc.2014.06.1155.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"7652_CR24","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1161\/CIRCULATIONAHA.112.000145","volume":"127","author":"F Roubille","year":"2013","unstructured":"Roubille F, Tardif J-C. New therapeutic targets in cardiology. Circulation. 2013;127(19):1986\u201396. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.000145.","journal-title":"Circulation"},{"issue":"3","key":"7652_CR25","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1161\/01.CIR.95.3.568","volume":"95","author":"E Cerbai","year":"1997","unstructured":"Cerbai E, Pino R, Porciatti F, et al. Characterization of the hyperpolarization-activated current, I<sub>f<\/sub>, in ventricular myocytes from human failing heart. Circulation. 1997;95(3):568\u201371. https:\/\/doi.org\/10.1161\/01.CIR.95.3.568.","journal-title":"Circulation"},{"issue":"2","key":"7652_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.yjmcc.2008.04.013","volume":"45","author":"F Stillitano","year":"2008","unstructured":"Stillitano F, Lonardo G, Zicha S, et al. Molecular basis of funny current (If) in normal and failing human heart. J Mol Cell Cardiol. 2008;45(2):289\u201399. https:\/\/doi.org\/10.1016\/j.yjmcc.2008.04.013.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"7652_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1161\/01.CIR.97.1.55","volume":"97","author":"UC Hoppe","year":"1998","unstructured":"Hoppe UC, Jansen E, S\u00fcdkamp M, Beuckelmann DJ. Hyperpolarization-activated inward current in ventricular myocytes from normal and failing human hearts. Circulation. 1998;97(1):55\u201365. https:\/\/doi.org\/10.1161\/01.CIR.97.1.55.","journal-title":"Circulation"},{"key":"7652_CR28","doi-asserted-by":"publisher","unstructured":"Kuwabara Y, Kuwahara K, Takano M, et al. Increased Expression of HCN Channels in the Ventricular Myocardium Contributes to Enhanced Arrhythmicity in Mouse Failing Hearts. J Am Heart Assoc. 2013;2(3):e000150. https:\/\/doi.org\/10.1161\/JAHA.113.000150.","DOI":"10.1161\/JAHA.113.000150"},{"issue":"23","key":"7652_CR29","doi-asserted-by":"publisher","first-page":"6310","DOI":"10.1093\/emboj\/cdg601","volume":"22","author":"K Kuwahara","year":"2003","unstructured":"Kuwahara K, Saito Y, Takano M, et al. NRSF regulates the fetal cardiac gene program and maintains normal cardiac structure and function. EMBO J. 2003;22(23):6310\u201321. https:\/\/doi.org\/10.1093\/emboj\/cdg601.","journal-title":"EMBO J"},{"issue":"6","key":"7652_CR30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/jcp.24507","volume":"229","author":"U Mackiewicz","year":"2014","unstructured":"Mackiewicz U, Gerges JY, Chu S, et al. Ivabradine protects against ventricular arrhythmias in acute myocardial infarction in the rat. J Cell Physiol. 2014;229(6):813\u201323. https:\/\/doi.org\/10.1002\/jcp.24507.","journal-title":"J Cell Physiol"},{"issue":"5","key":"7652_CR31","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/j.1476-5381.2011.01627.x","volume":"165","author":"S Suffredini","year":"2012","unstructured":"Suffredini S, Stillitano F, Comini L, et al. Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression. Br J Pharmacol. 2012;165(5):1457\u201366. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01627.x.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"7652_CR32","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.bbrc.2010.04.003","volume":"395","author":"S Xia","year":"2010","unstructured":"Xia S, Wang Y, Zhang Y, et al. Dynamic changes in HCN2, HCN4, KCNE1, and KCNE2 expression in ventricular cells from acute myocardial infarction rat hearts. Biochem Biophys Res Commun. 2010;395(3):330\u20135. https:\/\/doi.org\/10.1016\/j.bbrc.2010.04.003.","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"7652_CR33","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1161\/01.CIR.94.7.1674","volume":"94","author":"E Cerbai","year":"1996","unstructured":"Cerbai E, Barbieri M, Mugelli A. Occurrence and properties of the hyperpolarization-activated current If in ventricular myocytes from normotensive and hypertensive rats during aging. Circulation. 1996;94(7):1674\u201381. https:\/\/doi.org\/10.1161\/01.CIR.94.7.1674.","journal-title":"Circulation"},{"issue":"2","key":"7652_CR34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1113\/jphysiol.2003.041954","volume":"553","author":"M Fern\u00e1ndez-Velasco","year":"2003","unstructured":"Fern\u00e1ndez-Velasco M, Goren N, Benito G, Blanco-Rivero J, Bosc\u00e1 L, Delgado C. Regional distribution of hyperpolarization-activated current (If) and hyperpolarization-activated cyclic nucleotide-gated channel mRNA expression in ventricular cells from control and hypertrophied rat hearts. J Physiol. 2003;553(2):395\u2013405. https:\/\/doi.org\/10.1113\/jphysiol.2003.041954.","journal-title":"J Physiol"},{"issue":"4","key":"7652_CR35","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1124\/mol.105.020701","volume":"69","author":"J Stieber","year":"2006","unstructured":"Stieber J, Wieland K, St\u00f6ckl G, Ludwig A, Hofmann F. Bradycardic and proarrhythmic properties of sinus node inhibitors. Mol Pharmacol. 2006;69(4):1328\u201337.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"7652_CR36","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/j.1476-5381.1996.tb15505.x","volume":"118","author":"P Bois","year":"1996","unstructured":"Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol. 1996;118(4):1051.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"7652_CR37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1113\/jphysiol.2005.100776","volume":"572","author":"A Bucchi","year":"2006","unstructured":"Bucchi A, Tognati A, Milanesi R, Baruscotti M, DiFrancesco D. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. J Physiol. 2006;572(2):335\u201346.","journal-title":"J Physiol"},{"issue":"1","key":"7652_CR38","doi-asserted-by":"publisher","first-page":"e53132","DOI":"10.1371\/journal.pone.0053132","volume":"8","author":"A Bucchi","year":"2013","unstructured":"Bucchi A, Baruscotti M, Nardini M, et al. Identification of the molecular site of ivabradine binding to HCN4 channels. PLoS ONE. 2013;8(1):e53132.","journal-title":"PLoS ONE"},{"issue":"3","key":"7652_CR39","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ejphar.2011.07.025","volume":"668","author":"I Koncz","year":"2011","unstructured":"Koncz I, Sz\u00e9l T, Bitay M, et al. Electrophysiological effects of ivabradine in dog and human cardiac preparations: Potential antiarrhythmic actions. Eur J Pharmacol. 2011;668(3):419\u201326. https:\/\/doi.org\/10.1016\/j.ejphar.2011.07.025.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"7652_CR40","doi-asserted-by":"publisher","first-page":"e001813","DOI":"10.1161\/JAHA.115.001813","volume":"4","author":"D Melgari","year":"2015","unstructured":"Melgari D, Brack KE, Zhang C, et al. hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine. J Am Heart Assoc. 2015;4(4):e001813. https:\/\/doi.org\/10.1161\/JAHA.115.001813.","journal-title":"J Am Heart Assoc"},{"key":"7652_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.yjmcc.2015.05.009","volume":"85","author":"JP Lees-Miller","year":"2015","unstructured":"Lees-Miller JP, Guo J, Wang Y, Perissinotti LL, Noskov SY, Duff HJ. Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4. J Mol Cell Cardiol. 2015;85:71\u20138. https:\/\/doi.org\/10.1016\/j.yjmcc.2015.05.009.","journal-title":"J Mol Cell Cardiol"},{"issue":"4","key":"7652_CR42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1177\/2042098615595546","volume":"6","author":"JC Hancox","year":"2015","unstructured":"Hancox JC, Melgari D, Dempsey CE, Brack KE, Mitcheson J, Ng GA. hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes. Ther Adv Drug Safety. 2015;6(4):177\u20139. https:\/\/doi.org\/10.1177\/2042098615595546.","journal-title":"Ther Adv Drug Safety"},{"issue":"5","key":"7652_CR43","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1111\/j.1476-5381.1995.tb15002.x","volume":"115","author":"O P\u00e9rez","year":"1995","unstructured":"P\u00e9rez O, Gay P, Franqueza L, et al. Effects of the two enantiomers, S-16257-2 and S-16260-2, of a new bradycardic agent on guinea-pig isolated cardiac preparations. Br J Pharmacol. 1995;115(5):787\u201394. https:\/\/doi.org\/10.1111\/j.1476-5381.1995.tb15002.x.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"7652_CR44","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/jce.13772","volume":"30","author":"J Wang","year":"2019","unstructured":"Wang J, Yang YM, Li Y, et al. Long-term treatment with ivabradine in transgenic atrial fibrillation mice counteracts hyperpolarization-activated cyclic nucleotide gated channel overexpression. J Cardiovasc Electrophysiol. 2019;30(2):242\u201352. https:\/\/doi.org\/10.1111\/jce.13772.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"2","key":"7652_CR45","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0009-9236(98)90153-9","volume":"64","author":"I Ragueneau","year":"1998","unstructured":"Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck-Brentano C, Jaillon P. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther. 1998;64(2):192\u2013203.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"7652_CR46","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1074248415624157","volume":"21","author":"R Chaudhary","year":"2016","unstructured":"Chaudhary R, Garg J, Krishnamoorthy P, et al. Ivabradine: heart failure and beyond. J Cardiovasc Pharmacol Ther. 2016;21(4):335\u201343. https:\/\/doi.org\/10.1177\/1074248415624157.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"5","key":"7652_CR47","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/14740338.2019.1612873","volume":"18","author":"EA Bocchi","year":"2019","unstructured":"Bocchi EA, Salemi VMC. Ivabradine for treatment of heart failure. Expert Opin Drug Saf. 2019;18(5):393\u2013402. https:\/\/doi.org\/10.1080\/14740338.2019.1612873.","journal-title":"Expert Opin Drug Saf"},{"key":"7652_CR48","doi-asserted-by":"crossref","unstructured":"Mar PL, Horbal P, Chung MK, et al. Drug interactions affecting antiarrhythmic drug use. Circ: Arrhythmia Electrophysiol. 2022;15(5):e007955.","DOI":"10.1161\/CIRCEP.121.007955"},{"issue":"2","key":"7652_CR49","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1365-2710.2010.01170.x","volume":"36","author":"L Vlase","year":"2011","unstructured":"Vlase L, Neag M, Popa A, Muntean D, B\u00e2ldea I, Leucuta S. Pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers. J Clin Pharm Ther. 2011;36(2):225\u20139.","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"7652_CR50","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/BF03261904","volume":"32","author":"L Vlase","year":"2012","unstructured":"Vlase L, Popa A, Neag M, Muntean D, Leucuta SE. Pharmacokinetic interaction between ivabradine and phenytoin in healthy subjects. Clin Drug Investig. 2012;32(8):533\u20138. https:\/\/doi.org\/10.1007\/BF03261904.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"7652_CR51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/FJC.0b013e31816d5f49","volume":"52","author":"DG Wyse","year":"2008","unstructured":"Wyse DG. Therapeutic considerations in applying rate control therapy for atrial fibrillation. J Cardiovasc Pharmacol. 2008;52(1):11\u20137. https:\/\/doi.org\/10.1097\/FJC.0b013e31816d5f49.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10046","key":"7652_CR52","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/s0140-6736(16)31258-2","volume":"388","author":"IC Van Gelder","year":"2016","unstructured":"Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. Lancet. 2016;388(10046):818\u201328. https:\/\/doi.org\/10.1016\/s0140-6736(16)31258-2.","journal-title":"Lancet"},{"issue":"21","key":"7652_CR53","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1001\/jama.2020.23700","volume":"325","author":"JR Baman","year":"2021","unstructured":"Baman JR, Passman RS. Atrial Fibrillation. Jama. 2021;325(21):2218. https:\/\/doi.org\/10.1001\/jama.2020.23700.","journal-title":"Jama"},{"issue":"23","key":"7652_CR54","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa021375","volume":"347","author":"IC Van Gelder","year":"2002","unstructured":"Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834\u201340. https:\/\/doi.org\/10.1056\/NEJMoa021375.","journal-title":"N Engl J Med"},{"issue":"19","key":"7652_CR55","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"AJ Camm","year":"2010","unstructured":"Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369\u2013429. https:\/\/doi.org\/10.1093\/eurheartj\/ehq278.","journal-title":"Eur Heart J"},{"issue":"21","key":"7652_CR56","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","volume":"64","author":"CT January","year":"2014","unstructured":"January CT, Wann LS, Alpert JS, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-76. https:\/\/doi.org\/10.1016\/j.jacc.2014.03.022.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"7652_CR57","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1161\/cir.0000000000000139","volume":"130","author":"ED Peterson","year":"2014","unstructured":"Peterson ED, Ho PM, Barton M, et al. ACC\/AHA\/AACVPR\/AAFP\/ANA concepts for clinician-patient shared accountability in performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures. Circulation. 2014;130(22):1984\u201394. https:\/\/doi.org\/10.1161\/cir.0000000000000139.","journal-title":"Circulation"},{"issue":"11","key":"7652_CR58","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/europace\/eum191","volume":"9","author":"P Kirchhof","year":"2007","unstructured":"Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace. 2007;9(11):1006\u201323. https:\/\/doi.org\/10.1093\/europace\/eum191.","journal-title":"Europace"},{"issue":"5","key":"7652_CR59","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s00431-023-04891-8","volume":"182","author":"X Xu","year":"2023","unstructured":"Xu X, Guo Y, Gao W, Huang M, Liu T, Li F. Ivabradine monotherapy in pediatric patients with focal atrial tachycardia: a single-center study. Eur J Pediatr. 2023;182(5):2265\u201371.","journal-title":"Eur J Pediatr"},{"issue":"3","key":"7652_CR60","doi-asserted-by":"publisher","first-page":"030006052210817","DOI":"10.1177\/03000605221081727","volume":"50","author":"L Zhao","year":"2022","unstructured":"Zhao L, He R, Liu Y, She F, Xie Y, Zhang P. Report of a patient with refractory atrial tachycardia whose heart rate was controlled using ivabradine. J Int Med Res. 2022;50(3):03000605221081727.","journal-title":"J Int Med Res"},{"key":"7652_CR61","doi-asserted-by":"crossref","unstructured":"Banavalikar B, Shenthar J, Padmanabhan D, et al. Clinical and electrophysiological correlates of incessant ivabradine-sensitive atrial tachycardia. Circ: Arrhythmia Electrophysiol. 2019;12(8):e007387.","DOI":"10.1161\/CIRCEP.119.007387"},{"issue":"5","key":"7652_CR62","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612.","journal-title":"Eur Heart J"},{"issue":"1","key":"7652_CR63","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104\u201332. https:\/\/doi.org\/10.1016\/j.jacc.2019.01.011.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"7652_CR64","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1160\/th12-03-0175","volume":"107","author":"JB Olesen","year":"2012","unstructured":"Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0\u20131: a nationwide cohort study. Thromb Haemost. 2012;107(6):1172\u20139. https:\/\/doi.org\/10.1160\/th12-03-0175.","journal-title":"Thromb Haemost"},{"issue":"2","key":"7652_CR65","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/jce.13788","volume":"30","author":"SN Koenig","year":"2019","unstructured":"Koenig SN, Mohler PJ. Potential use of ivabradine for treatment of atrial fibrillation. J Cardiovasc Electrophysiol. 2019;30(2):253\u20134. https:\/\/doi.org\/10.1111\/jce.13788.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"7652_CR66","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ijcard.2016.08.100","volume":"223","author":"Y Lu","year":"2016","unstructured":"Lu Y, Li K, Liu XS, Zhang N, Li G, Liu T. Ivabradine and atrial fibrillation: a double-edged sword. Int J Cardiol. 2016;223:182\u20135. https:\/\/doi.org\/10.1016\/j.ijcard.2016.08.100.","journal-title":"Int J Cardiol"},{"issue":"6","key":"7652_CR67","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1177\/1753944716669658","volume":"10","author":"SL Turley","year":"2016","unstructured":"Turley SL, Francis KE, Lowe DK, Cahoon WD Jr. Emerging role of ivabradine for rate control in atrial fibrillation. Ther Adv Cardiovasc Dis. 2016;10(6):348\u201352. https:\/\/doi.org\/10.1177\/1753944716669658.","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"3","key":"7652_CR68","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/jce.12569","volume":"26","author":"RL Verrier","year":"2015","unstructured":"Verrier RL, Silva AF, Bonatti R, et al. Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation. J Cardiovasc Electrophysiol. 2015;26(3):329\u201335. https:\/\/doi.org\/10.1111\/jce.12569.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"18","key":"7652_CR69","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1161\/01.CIR.100.18.1879","volume":"100","author":"S-A Chen","year":"1999","unstructured":"Chen S-A, Hsieh M-H, Tai C-T, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation. 1999;100(18):1879\u201386.","journal-title":"Circulation"},{"key":"7652_CR70","doi-asserted-by":"crossref","unstructured":"Suenari K, Cheng CC, Chen YC, et al. Effects of ivabradine on the pulmonary vein electrical activity and modulation of pacemaker currents and calcium homeostasis. J Cardiovasc Electrophysiol. 2012;23(2):200\u20136.","DOI":"10.1111\/j.1540-8167.2011.02173.x"},{"issue":"11","key":"7652_CR71","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1111\/j.1540-8167.2007.00955.x","volume":"18","author":"A El Chemaly","year":"2007","unstructured":"El Chemaly A, Magaud C, Patri S, Jayle C, Guinamard R, Bois P. The heart rate-lowering agent ivabradine inhibits the pacemaker current I(f) in human atrial myocytes. J Cardiovasc Electrophysiol. 2007;18(11):1190\u20136. https:\/\/doi.org\/10.1111\/j.1540-8167.2007.00955.x.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"7652_CR72","doi-asserted-by":"publisher","unstructured":"Li YD, Ji YT, Zhou XH, et al. Effects of ivabradine on cardiac electrophysiology in dogs with age-related atrial fibrillation. Med Sci Monit. 2015;21:1414\u201320. https:\/\/doi.org\/10.12659\/msm.894320.","DOI":"10.12659\/msm.894320"},{"issue":"6","key":"7652_CR73","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.ejheart.2008.04.005","volume":"10","author":"GM De Ferrari","year":"2008","unstructured":"De Ferrari GM, Mazzuero A, Agnesina L, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail. 2008;10(6):550\u20135. https:\/\/doi.org\/10.1016\/j.ejheart.2008.04.005.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"7652_CR74","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000073933","volume":"100","author":"M Manz","year":"2003","unstructured":"Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100(3):149\u201355. https:\/\/doi.org\/10.1159\/000073933.","journal-title":"Cardiology"},{"key":"7652_CR75","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ijcard.2017.02.055","volume":"236","author":"G Frommeyer","year":"2017","unstructured":"Frommeyer G, Sterneberg M, Dechering DG, et al. Effective suppression of atrial fibrillation by ivabradine: Novel target for an established drug? Int J Cardiol. 2017;236:237\u201343. https:\/\/doi.org\/10.1016\/j.ijcard.2017.02.055.","journal-title":"Int J Cardiol"},{"key":"7652_CR76","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijcard.2014.10.062","volume":"179","author":"J Kosiuk","year":"2015","unstructured":"Kosiuk J, Oebel S, John S, Hilbert S, Hindricks G, Bollmann A. Ivabradine for rate control in atrial fibrillation. Int J Cardiol. 2015;179:27\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2014.10.062.","journal-title":"Int J Cardiol"},{"key":"7652_CR77","doi-asserted-by":"publisher","unstructured":"Hardison E, Cox ZL, Heckman K, Kelly PA, Lindenfeld J. A case report of ivabradine used for heart rate control of atrial fibrillation in acute decompensated heart failure. Eur Heart J Case Rep. 2022;6(2):ytac077. https:\/\/doi.org\/10.1093\/ehjcr\/ytac077.","DOI":"10.1093\/ehjcr\/ytac077"},{"key":"7652_CR78","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ijcard.2017.04.071","volume":"247","author":"C Fossati","year":"2017","unstructured":"Fossati C, Volterrani M, Punzo N, Campolongo G, Cascelli G, Caminiti G. Dose-dependent effects of ivabradine on heart rate during maximal efforts in a woman with permanent atrial fibrillation. Int J Cardiol. 2017;247:37. https:\/\/doi.org\/10.1016\/j.ijcard.2017.04.071.","journal-title":"Int J Cardiol"},{"issue":"6","key":"7652_CR79","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/jce.12974","volume":"27","author":"Z Abdel-Salam","year":"2016","unstructured":"Abdel-Salam Z, Nammas W. Atrial fibrillation after coronary artery bypass surgery: can ivabradine reduce its occurrence? J Cardiovasc Electrophysiol. 2016;27(6):670\u20136. https:\/\/doi.org\/10.1111\/jce.12974.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"7652_CR80","doi-asserted-by":"publisher","DOI":"10.1136\/pmj-2022-141948.10.1136\/pmj-2022-141948","author":"WS Hu","year":"2022","unstructured":"Hu WS, Lin CL. Beta blocker versus ivabradine for cardiovascular outcomes among patients with atrial fibrillation. Postgrad Med J. 2022. https:\/\/doi.org\/10.1136\/pmj-2022-141948.10.1136\/pmj-2022-141948.","journal-title":"Postgrad Med J"},{"key":"7652_CR81","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ijcard.2015.08.207","volume":"202","author":"G Caminiti","year":"2016","unstructured":"Caminiti G, Fossati C, Rosano G, Volterrani M. Addition of ivabradine to betablockers in patients with atrial fibrillation: effects on heart rate and exercise tolerance. Int J Cardiol. 2016;202:73\u20134. https:\/\/doi.org\/10.1016\/j.ijcard.2015.08.207.","journal-title":"Int J Cardiol"},{"issue":"4","key":"7652_CR82","first-page":"373","volume":"40","author":"W-C Lin","year":"2024","unstructured":"Lin W-C, Peng P-S, Lin S-L. Feasibility of short-term use of ivabradine in critical ill patients who have atrial fibrillation and tachycardia. Acta Cardiologica Sinica. 2024;40(4):373.","journal-title":"Acta Cardiologica Sinica"},{"issue":"5","key":"7652_CR83","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ihj.2023.08.006","volume":"75","author":"A Katheria","year":"2023","unstructured":"Katheria A, Kapoor A, Sahu A, et al. A pilot study evaluating the role of ivabradine for rate control in patients with rheumatic atrial fibrillation. Indian Heart J. 2023;75(5):376\u201382. https:\/\/doi.org\/10.1016\/j.ihj.2023.08.006.","journal-title":"Indian Heart J"},{"issue":"6","key":"7652_CR84","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.hrthm.2023.02.012","volume":"20","author":"A Fontenla","year":"2023","unstructured":"Fontenla A, Tamargo J, Salgado R, et al. Ivabradine for controlling heart rate in permanent atrial fibrillation: a translational clinical trial. Heart Rhythm. 2023;20(6):822\u201330. https:\/\/doi.org\/10.1016\/j.hrthm.2023.02.012.","journal-title":"Heart Rhythm"},{"key":"7652_CR85","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ijcard.2016.09.044","volume":"224","author":"W Wongcharoen","year":"2016","unstructured":"Wongcharoen W, Ruttanaphol A, Gunaparn S, Phrommintikul A. Ivabradine reduced ventricular rate in patients with non-paroxysmal atrial fibrillation. Int J Cardiol. 2016;224:252\u20135. https:\/\/doi.org\/10.1016\/j.ijcard.2016.09.044.","journal-title":"Int J Cardiol"},{"issue":"4","key":"7652_CR86","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1002\/ehf2.13966","volume":"9","author":"YS Lin","year":"2022","unstructured":"Lin YS, Jan JY, Chang JJ, et al. Ivabradine in heart failure patients with reduced ejection fraction and history of paroxysmal atrial fibrillation. ESC Heart Fail. 2022;9(4):2548\u201357. https:\/\/doi.org\/10.1002\/ehf2.13966.","journal-title":"ESC Heart Fail"},{"issue":"11","key":"7652_CR87","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.cardfail.2018.09.016","volume":"24","author":"CS Chan","year":"2018","unstructured":"Chan CS, Chen YC, Chang SL, et al. Heart failure differentially modulates the effects of ivabradine on the electrical activity of the sinoatrial node and pulmonary veins. J Card Fail. 2018;24(11):763\u201372. https:\/\/doi.org\/10.1016\/j.cardfail.2018.09.016.","journal-title":"J Card Fail"},{"issue":"1","key":"7652_CR88","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40119-013-0024-1","volume":"3","author":"L Iliuta","year":"2014","unstructured":"Iliuta L, Rac-Albu M. Ivabradine versus beta-blockers in patients with conduction abnormalities or left ventricular dysfunction undergoing cardiac surgery. Cardio Ther. 2014;3(1):13\u201326. https:\/\/doi.org\/10.1007\/s40119-013-0024-1.","journal-title":"Cardio Ther"},{"key":"7652_CR89","doi-asserted-by":"publisher","unstructured":"Tekin EE, Ye\u015filta\u015f MA, Haberal \u0130. Short-term results of ivabradine versus metoprolol: the effects on atrial fibrillation in patients undergoing off-pump coronary artery bypass grafting. Braz J Cardiovasc Surg. 2022;37(6):857\u201365. https:\/\/doi.org\/10.21470\/1678-9741-2021-0201.","DOI":"10.21470\/1678-9741-2021-0201"},{"issue":"46","key":"7652_CR90","first-page":"3291","volume":"36","author":"K Fox","year":"2015","unstructured":"Fox K, Ford I, Steg PG, Tardif J-C, Tendera M, Ferrari R. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. Eur Heart J. 2015;36(46):3291\u20136.","journal-title":"Eur Heart J"},{"issue":"18","key":"7652_CR91","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1161\/01.Cir.0000065578.00869.7c","volume":"107","author":"A Burashnikov","year":"2003","unstructured":"Burashnikov A, Antzelevitch C. Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation. 2003;107(18):2355\u201360. https:\/\/doi.org\/10.1161\/01.Cir.0000065578.00869.7c.","journal-title":"Circulation"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07652-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-024-07652-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-024-07652-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:00:32Z","timestamp":1766127632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-024-07652-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7652"],"URL":"https:\/\/doi.org\/10.1007\/s10557-024-07652-3","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]},"assertion":[{"value":"12 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In this review, we determined that adherence to a formal ethics code was not required due to the nature of the research. The study involved a systematic analysis of existing literature and publicly available data, which did not necessitate direct interaction with human participants or the collection of sensitive personal information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors affirm that they have no conflict of interest\u00a0to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}